Why the study?
Inflammation plays a key role in ACS, and leukocytes and leukocyte ratios are recognized inflammatory markers, but the prognostic value of combining MLR with NLR in NSTEMI needed evaluation.
Does the combination of high monocyte-to-lymphocyte ratio and high neutrophil-to-lymphocyte ratio predict long-term MACE in patients with NSTEMI undergoing primary PCI?
Does the combination of high monocyte-to-lymphocyte ratio and high neutrophil-to-lymphocyte ratio predict long-term MACE in patients with NSTEMI undergoing primary PCI?
The combination of monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio serves as a simple, non-invasive prognostic biomarker for predicting long-term MACE in patients with NSTEMI undergoing primary PCI.
Hypothesis-generating for combined MLR-NLR in NSTEMI MACE prediction; should not yet change practice.
Inflammation plays a key role in the development of atherosclerosis and in the pathogenesis of acute coronary syndrome (ACS). Leukocytes and leukocytes ratios were recognized as inflammatory markers in predicting the presence and severity of ACS. This study aimed to evaluate prognostic value of the combination of monocyte-to-lymphocyte ratio (MLR) with ratio neutrophil-to-lymphocyte (NLR) for predicting long-term major adverse cardiac events (MACE) in patients with non-ST elevated myocardial infarction (NSTEMI), using data from cardiology department data of 183 patients with NSTEMI undergoing primary PCI between January 2018 and August 2021.
No takes yet. Share an insight, caveat, or question.
Qadi et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: